

**From:** Pietari Ripatti [pietari.ripatti@gmail.com](mailto:pietari.ripatti@gmail.com)  
**Subject:** Re: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 16.1.2020 at 15.54  
**To:** Pietari Ripatti [pietari.ripatti@helsinki.fi](mailto:pietari.ripatti@helsinki.fi)



I myself also agree to adding the co-authors mentioned below.

Pietari

On 16.1.2020, at 7.06, Pietari Ripatti <[pietari.ripatti@gmail.com](mailto:pietari.ripatti@gmail.com)> wrote:

Dear co-authors,

As per journal's policy, I'd require your statement attesting to your agreement to add new authors to the manuscript. During the first major revision, we added four additional authors: Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén. Yu, Jake, and Taru were responsible for performing the revised lipid GWAS in the UKBB. Elisabeth is the co-lead-PI for GeneRISK, in which the optimal rho parameter for LDpred was tested. Their contributions were very substantial and I think they deserve author status.

Please email the statements directly to me and I'll forward them to the journal all at once. As we want to get the submission going as soon as possible, please reply as soon as you can.

Thank you!

Best regards,  
Pietari

Begin forwarded message:

**From:** "Ripatti, Samuli" <[samuli.ripatti@helsinki.fi](mailto:samuli.ripatti@helsinki.fi)>  
**Subject:** Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 15.1.2020 at 22.53.26 EET  
**To:** "Ripatti, Jaakko P" <[pietari.ripatti@helsinki.fi](mailto:pietari.ripatti@helsinki.fi)>

Sent from my iPhone

Begin forwarded message:

**From:** "martin.banigan@heart.org" <[martin.banigan@heart.org](mailto:martin.banigan@heart.org)>  
**Date:** 15. January 2020 at 15.08.06 GMT-5  
**To:** "Ripatti, Samuli" <[samuli.ripatti@helsinki.fi](mailto:samuli.ripatti@helsinki.fi)>  
**Subject:** CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Reply-To:** [martin.banigan@heart.org](mailto:martin.banigan@heart.org)

Dear Prof. Ripatti,

In checking in your manuscript submitted to *Circulation: Genomic and Precision Medicine* it has come to our attention that the following must be addressed before we can release your manuscript to the Editor for consideration.

1. Per journal policy, if an author(s) is added to the manuscript, all other authors must provide a statement attesting to his/her agreement to the changes. Thus, all authors must approve the addition of the four authors added in the previous iteration of this manuscript. The statements can be emailed to [martin.banigan@heart.org](mailto:martin.banigan@heart.org). Alternatively, the statements can be uploaded as supplemental material.
2. If possible, please provide the final figures in TIF or EPS file format.
3. You must use the following symbols in the following order for the footnotes of your figures: \*, †, ‡, {section sign}, ll, #, \*\*, ††, ‡‡, etc.
4. Please remove the figure and table placeholders in the manuscript. Each item should only be cited parenthetically--the publisher will place the figures and tables where needed.
5. Please relabel the supplemental figures and tables--"Figure S1", etc. as opposed to "S1 Figure".

Your paper has been placed back in the Author Approval Folder where you may access via the following link:

<https://circgen-submit.aha-journals.org/cgi-bin/main.plex?el=A3Hp6CaZi6C4QGB4F6A9ftdEyMaduU0qeXTPbO9vTASEwZ>

Please make the correction(s) as specified above and resubmit your paper following the same steps as before.

If you have any questions please feel free to contact me.

**From:** joel.ramo joel.ramo@helsinki.fi  
**Subject:** RE: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 16.1.2020 at 8.20  
**To:** Pietari Ripatti pietari.ripatti@gmail.com



Hi Pietari,  
I fully agree with adding Yu Fu, Jake Lin, Taru Tukiainen and Elisabeth Widén as authors.  
Joel

----- Original message -----

**From:** Pietari Ripatti <pietari.ripatti@gmail.com>  
**Date:** 16/01/2020 07:06 (GMT+02:00)  
**To:** Joel Rämö <joel.ramo@helsinki.fi>, Nina Mars <nina.mars@helsinki.fi>, Sanni Söderlund <sanni.soderlund@helsinki.fi>, Sanni Söderlund <sanni.soderlund@hus.fi>, Christian Benner <christian.benner@helsinki.fi>, Isurakka <isurakka@umich.edu>, Tuomo Kiiskinen <tuomo.kiiskinen@helsinki.fi>, "Havulinna, Aki S" <aki.havulinna@helsinki.fi>, Priit Palta <priit.palta@helsinki.fi>, "Freimer, Nelson B." <NFreimer@mednet.ucla.edu>, Salomaa Veikko <veikko.salomaa@thl.fi>, Matti Pirinen <matti.pirinen@helsinki.fi>, "Palotie, Aarno" <aarno.palotie@helsinki.fi>, "Taskinen, Marja-Riitta" <marja-riitta.taskinen@helsinki.fi>, Samuli Ripatti <samuli.ripatti@helsinki.fi>  
**Subject:** ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission

Dear co-authors,

As per journal's policy, I'd require your statement attesting to your agreement to add new authors to the manuscript. During the first major revision, we added four additional authors: Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén. Yu, Jake, and Taru were responsible for performing the revised lipid GWAS in the UKBB. Elisabeth is the co-lead-PI for GeneRISK, in which the optimal rho parameter for LDpred was tested. Their contributions were very substantial and I think they deserve author status.

Please email the statements directly to me and I'll forward them to the journal all at once. As we want to get the submission going as soon as possible, please reply as soon as you can.

Thank you!

Best regards,  
Pietari

Begin forwarded message:

**From:** "Ripatti, Samuli" <samuli.ripatti@helsinki.fi>  
**Subject:** Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 15.1.2020 at 22.53.26 EET  
**To:** "Ripatti, Jaakko P" <pietari.ripatti@helsinki.fi>

Sent from my iPhone

Begin forwarded message:

**From:** "martin.banigan@heart.org" <martin.banigan@heart.org>  
**Date:** 15. January 2020 at 15.08.06 GMT-5  
**To:** "Ripatti, Samuli" <samuli.ripatti@helsinki.fi>  
**Subject:** CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Reply-To:** martin.banigan@heart.org

Dear Prof. Ripatti,

In checking in your manuscript submitted to *Circulation: Genomic and Precision Medicine* it has come to our attention that the following must be addressed before we can release your manuscript to the Editor for consideration.

1. Per journal policy, if an author(s) is added to the manuscript, all other authors must provide a statement attesting to his/her agreement to the changes. Thus, all authors must approve the addition of the four authors added in the previous iteration of this manuscript. The statements can be emailed to [martin.banigan@heart.org](mailto:martin.banigan@heart.org). Alternatively, the statements can be uploaded as supplemental material.
2. If possible, please provide the final figures in TIF or EPS file format.
3. You must use the following symbols in the following order for the footnotes of your figures: \*, †, ‡, {section sign}, ll, #, \*\*, ††, ‡‡, etc.
4. Please remove the figure and table placeholders in the manuscript. Each item should only be cited parenthetically--the publisher will place the figures and tables where needed.
5. Please relabel the supplemental figures and tables--"Figure S1", etc. as opposed to "S1 Figure".

Your paper has been placed back in the Author Approval Folder where you may access via the following link:

**From:** Mars, Nina J [nina.mars@helsinki.fi](mailto:nina.mars@helsinki.fi)  
**Subject:** Re: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 16.1.2020 at 7.58  
**To:** Pietari Ripatti [pietari.ripatti@gmail.com](mailto:pietari.ripatti@gmail.com)



I approve the addition of Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén to the manuscript.

Nina Mars, MD, PhD  
Postdoctoral researcher  
Institute for Molecular Medicine Finland (FIMM)  
HiLIFE, University of Helsinki  
[nina.mars@helsinki.fi](mailto:nina.mars@helsinki.fi)

---

**From:** Pietari Ripatti <[pietari.ripatti@gmail.com](mailto:pietari.ripatti@gmail.com)>  
**Sent:** Thursday, January 16, 2020 7:06:16 AM  
**To:** Rämö, Joel A T; Mars, Nina J; Söderlund, Sanni M; Sanni Söderlund; Benner, Christian; [isurakka@umich.edu](mailto:isurakka@umich.edu); Kiiskinen, Tuomo T J; Havulinna, Aki S; Palta, Priit; Freimer, Nelson B.; Salomaa Veikko; Pirinen, Matti J; Palotie, Aarno; Taskinen, Marja-Riitta; Ripatti, Samuli  
**Subject:** ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission

Dear co-authors,

As per journal's policy, I'd require your statement attesting to your agreement to add new authors to the manuscript. During the first major revision, we added four additional authors: Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén. Yu, Jake, and Taru were responsible for performing the revised lipid GWAS in the UKBB. Elisabeth is the co-lead-PI for GeneRISK, in which the optimal rho parameter for LDpred was tested. Their contributions were very substantial and I think they deserve author status.

Please email the statements directly to me and I'll forward them to the journal all at once. As we want to get the submission going as soon as possible, please reply as soon as you can.

Thank you!

Best regards,  
Pietari

Begin forwarded message:

**From:** "Ripatti, Samuli" <[samuli.ripatti@helsinki.fi](mailto:samuli.ripatti@helsinki.fi)>  
**Subject:** Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 15.1.2020 at 22.53.26 EET  
**To:** "Ripatti, Jaakko P" <[pietari.ripatti@helsinki.fi](mailto:pietari.ripatti@helsinki.fi)>

**From:** Söderlund, Sanni M sannni.soderlund@helsinki.fi  
**Subject:** Re: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 16.1.2020 at 7.16  
**To:** Pietari Ripatti pietari.ripatti@gmail.com

---



Dear Pietari

I hereby state that I fully agree with adding Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén as authors to this manuscript.

Best regards

Sanni Söderlund

**From:** Benner, Christian christian.benner@helsinki.fi  
**Subject:** Re: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 16.1.2020 at 16.00  
**To:** Pietari Ripatti pietari.ripatti@gmail.com

CB

Dear Pietari,

I agree with the addition of further coauthors.

Thanks,

Christian

On 16. Jan 2020, at 0.06, Pietari Ripatti <pietari.ripatti@gmail.com> wrote:

Dear co-authors,

As per journal's policy, I'd require your statement attesting to your agreement to add new authors to the manuscript. During the first major revision, we added four additional authors: Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén. Yu, Jake, and Taru were responsible for performing the revised lipid GWAS in the UKBB. Elisabeth is the co-lead-PI for GeneRISK, in which the optimal rho parameter for LDpred was tested. Their contributions were very substantial and I think they deserve author status.

Please email the statements directly to me and I'll forward them to the journal all at once. As we want to get the submission going as soon as possible, please reply as soon as you can.

Thank you!

Best regards,  
Pietari

Begin forwarded message:

**From:** "Ripatti, Samuli" <samuli.ripatti@helsinki.fi>  
**Subject:** Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 15.1.2020 at 22.53.26 EET  
**To:** "Ripatti, Jaakko P" <pietari.ripatti@helsinki.fi>

Sent from my iPhone

Begin forwarded message:

**From:** "martin.banigan@heart.org" <martin.banigan@heart.org>  
**Date:** 15. January 2020 at 15.08.06 GMT-5  
**To:** "Ripatti, Samuli" <samuli.ripatti@helsinki.fi>  
**Subject:** CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Reply-To:** martin.banigan@heart.org

Dear Prof. Ripatti,

In checking in your manuscript submitted to *Circulation: Genomic and Precision Medicine* it has come to our attention that the following must be addressed before we can release your manuscript to the Editor for consideration.

1. Per journal policy, if an author(s) is added to the manuscript, all other authors must provide a statement attesting to his/her agreement to the changes. Thus, all authors must approve the addition of the four authors added in the previous iteration of this manuscript. The statements can be emailed to [martin.banigan@heart.org](mailto:martin.banigan@heart.org). Alternatively, the statements can be uploaded as supplemental material.
2. If possible, please provide the final figures in TIF or EPS file format.
3. You must use the following symbols in the following order for the footnotes of your figures: \*, †, ‡, {section sign}, ll, #, \*\*, ††, ‡‡, etc.
4. Please remove the figure and table placeholders in the manuscript. Each item should only be cited parenthetically--the publisher will place the figures and tables where needed.
5. Please relabel the supplemental figures and tables--"Figure S1", etc. as opposed to "S1 Figure".

Your paper has been placed back in the Author Approval Folder where you may access via the following link:

[https://circgen-submit.aha-journals.org/cgi-bin/main.plex?  
el=A3Hp6CaZi6C4QGB4F6A9fdEyMaduU0qeXTPbO9vTASEwZ](https://circgen-submit.aha-journals.org/cgi-bin/main.plex?el=A3Hp6CaZi6C4QGB4F6A9fdEyMaduU0qeXTPbO9vTASEwZ)

**From:** Ida Surakka isurakka@umich.edu  
**Subject:** Re: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 16.1.2020 at 11.13  
**To:** Pietari Ripatti pietari.ripatti@gmail.com

IS

Hi Pietari,

I agree to the listed co-authors to be added to the author list

-Ida

On 16. Jan 2020, at 6.06, Pietari Ripatti <pietari.ripatti@gmail.com> wrote:

Dear co-authors,

As per journal's policy, I'd require your statement attesting to your agreement to add new authors to the manuscript. During the first major revision, we added four additional authors: Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén. Yu, Jake, and Taru were responsible for performing the revised lipid GWAS in the UKBB. Elisabeth is the co-lead-PI for GeneRISK, in which the optimal rho parameter for LDpred was tested. Their contributions were very substantial and I think they deserve author status.

Please email the statements directly to me and I'll forward them to the journal all at once. As we want to get the submission going as soon as possible, please reply as soon as you can.

Thank you!

Best regards,  
Pietari

Begin forwarded message:

**From:** "Ripatti, Samuli" <samuli.ripatti@helsinki.fi>  
**Subject:** Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 15.1.2020 at 22.53.26 EET  
**To:** "Ripatti, Jaakko P" <pietari.ripatti@helsinki.fi>

Sent from my iPhone

Begin forwarded message:

**From:** "martin.banigan@heart.org" <martin.banigan@heart.org>  
**Date:** 15. January 2020 at 15.08.06 GMT-5  
**To:** "Ripatti, Samuli" <samuli.ripatti@helsinki.fi>  
**Subject:** CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Reply-To:** martin.banigan@heart.org

Dear Prof. Ripatti,

In checking in your manuscript submitted to *Circulation: Genomic and Precision Medicine* it has come to our attention that the following must be addressed before we can release your manuscript to the Editor for consideration.

1. Per journal policy, if an author(s) is added to the manuscript, all other authors must provide a statement attesting to his/her agreement to the changes. Thus, all authors must approve the addition of the four authors added in the previous iteration of this manuscript. The statements can be emailed to [martin.banigan@heart.org](mailto:martin.banigan@heart.org). Alternatively, the statements can be uploaded as supplemental material.
2. If possible, please provide the final figures in TIF or EPS file format.
3. You must use the following symbols in the following order for the footnotes of your figures: \*, †, ‡, {section sign}, ll, #, \*\*, ††, ‡‡, etc.
4. Please remove the figure and table placeholders in the manuscript. Each item should only be cited parenthetically--the publisher will place the figures and tables where needed.
5. Please relabel the supplemental figures and tables--"Figure S1", etc. as opposed to "S1 Figure".

Your paper has been placed back in the Author Approval Folder where you may access via the following link:

[https://circgen-submit.aha-journals.org/cgi-bin/main.plex?  
el=A3Hp6CaZi6C4QGB4F6A9fdEyMaduU0qeXTPbO9vTASEwZ](https://circgen-submit.aha-journals.org/cgi-bin/main.plex?el=A3Hp6CaZi6C4QGB4F6A9fdEyMaduU0qeXTPbO9vTASEwZ)

**From:** Kiiskinen, Tuomo T J [tuomo.kiiskinen@helsinki.fi](mailto:tuomo.kiiskinen@helsinki.fi)  
**Subject:** VS: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 16.1.2020 at 11.17



**To:** Taskinen, Marja-Riitta [marja-riitta.taskinen@helsinki.fi](mailto:marja-riitta.taskinen@helsinki.fi), Pietari Ripatti [pietari.ripatti@gmail.com](mailto:pietari.ripatti@gmail.com), Rämö, Joel A T [joel.ramo@helsinki.fi](mailto:joel.ramo@helsinki.fi), Mars, Nina J [nina.mars@helsinki.fi](mailto:nina.mars@helsinki.fi), Söderlund, Sanni M [sanni.soderlund@helsinki.fi](mailto:sanni.soderlund@helsinki.fi), Sanni Söderlund [sanni.soderlund@hus.fi](mailto:sanni.soderlund@hus.fi), Benner, Christian [christian.benner@helsinki.fi](mailto:christian.benner@helsinki.fi), [isurakka@umich.edu](mailto:isurakka@umich.edu), Havulinna, Aki S [aki.havulinna@helsinki.fi](mailto:aki.havulinna@helsinki.fi), Palta, Priit [priit.palta@helsinki.fi](mailto:priit.palta@helsinki.fi), Freimer, Nelson B. [NFreimer@mednet.ucla.edu](mailto:NFreimer@mednet.ucla.edu), Salomaa Veikko [veikko.salomaa@thl.fi](mailto:veikko.salomaa@thl.fi), Pirinen, Matti J [matti.pirinen@helsinki.fi](mailto:matti.pirinen@helsinki.fi), Palotie, Aarno [aarno.palotie@helsinki.fi](mailto:aarno.palotie@helsinki.fi), Ripatti, Samuli [samuli.ripatti@helsinki.fi](mailto:samuli.ripatti@helsinki.fi)

Dear Pietari,

I agree with the author addition.

best,  
Tuomo

---

**Lähettäjä:** Taskinen, Marja-Riitta

**Lähetetty:** 16. tammikuuta 2020 10:43:08

**Vastaanottaja:** Pietari Ripatti; Rämö, Joel A T; Mars, Nina J; Söderlund, Sanni M; Sanni Söderlund; Benner, Christian; [isurakka@umich.edu](mailto:isurakka@umich.edu); Kiiskinen, Tuomo T J; Havulinna, Aki S; Palta, Priit; Freimer, Nelson B.; Salomaa Veikko; Pirinen, Matti J; Palotie, Aarno; Ripatti, Samuli

**Aihe:** RE: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission

Dear Joel and Samuli

I do agree with the author status of the added co-authors :Yu Fu, Jake LIN ,Taru Tukiainen and Elisabeth Widen .  
with kind regards  
Marja-Riitta

Marja-Riitta Taskinen  
Professor of Medicine  
University of Helsinki  
Research Programs Unit  
Biomedicum  
Haartmaninkatu 8, P.O.Box 700  
00029 Helsinki, Finland  
Tel: +358-9-4717 1990  
Fax: +358-9-4717 1992  
E-mail: [marja-riitta.taskinen@helsinki.fi](mailto:marja-riitta.taskinen@helsinki.fi)

---

**From:** Pietari Ripatti <[pietari.ripatti@gmail.com](mailto:pietari.ripatti@gmail.com)>

**Sent:** torstai 16. tammikuuta 2020 7.06

**To:** Rämö, Joel A T <[joel.ramo@helsinki.fi](mailto:joel.ramo@helsinki.fi)>; Mars, Nina J <[nina.mars@helsinki.fi](mailto:nina.mars@helsinki.fi)>; Söderlund, Sanni M <[sanni.soderlund@helsinki.fi](mailto:sanni.soderlund@helsinki.fi)>; Sanni Söderlund <[sanni.soderlund@hus.fi](mailto:sanni.soderlund@hus.fi)>; Benner, Christian <[christian.benner@helsinki.fi](mailto:christian.benner@helsinki.fi)>; [isurakka@umich.edu](mailto:isurakka@umich.edu); Kiiskinen, Tuomo T J <[tuomo.kiiskinen@helsinki.fi](mailto:tuomo.kiiskinen@helsinki.fi)>; Havulinna, Aki S <[aki.havulinna@helsinki.fi](mailto:aki.havulinna@helsinki.fi)>; Palta, Priit <[priit.palta@helsinki.fi](mailto:priit.palta@helsinki.fi)>; Freimer, Nelson B. <[NFreimer@mednet.ucla.edu](mailto:NFreimer@mednet.ucla.edu)>; Salomaa Veikko <[veikko.salomaa@thl.fi](mailto:veikko.salomaa@thl.fi)>; Pirinen, Matti J <[matti.pirinen@helsinki.fi](mailto:matti.pirinen@helsinki.fi)>; Palotie, Aarno <[aarno.palotie@helsinki.fi](mailto:aarno.palotie@helsinki.fi)>; Taskinen, Marja-Riitta <[marja-riitta.taskinen@helsinki.fi](mailto:marja-riitta.taskinen@helsinki.fi)>; Ripatti, Samuli

**From:** Havulinna, Aki S <aki.havulinna@helsinki.fi>  
**Subject:** Re: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 16.1.2020 at 8.54  
**To:** Pietari Ripatti <pietari.ripatti@gmail.com>

AH

Agreed.  
Aki

---

**From:** Pietari Ripatti <pietari.ripatti@gmail.com>  
**Date:** Thursday, 16 January 2020 at 7.06  
**To:** Joel <joel.ramo@helsinki.fi>, "Mars, Nina J" <nina.mars@helsinki.fi>, "Söderlund, Sanni M" <sanni.soderlund@helsinki.fi>, Sanni Söderlund <sanni.soderlund@hus.fi>, Christian Benner <christian.benner@helsinki.fi>, "isurakka@umich.edu" <isurakka@umich.edu>, "Kiiskinen, Tuomo T J" <tuomo.kiiskinen@helsinki.fi>, "aki.havulinna@helsinki.fi" <aki.havulinna@helsinki.fi>, "priit.palta@helsinki.fi" <priit.palta@helsinki.fi>, Nelson Freimer <NFreimer@mednet.ucla.edu>, Salomaa Veikko <veikko.salomaa@thl.fi>, Matti Pirinen <matti.pirinen@helsinki.fi>, Aarno Palotie <aarno.palotie@helsinki.fi>, "marja-riitta.taskinen@helsinki.fi" <marja-riitta.taskinen@helsinki.fi>, Samuli Ripatti <samuli.ripatti@helsinki.fi>  
**Subject:** ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission

Dear co-authors,

As per journal's policy, I'd require your statement attesting to your agreement to add new authors to the manuscript. During the first major revision, we added four additional authors: Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén. Yu, Jake, and Taru were responsible for performing the revised lipid GWAS in the UKBB. Elisabeth is the co-lead-PI for GeneRISK, in which the optimal rho parameter for LDpred was tested. Their contributions were very substantial and I think they deserve author status.

Please email the statements directly to me and I'll forward them to the journal all at once. As we want to get the submission going as soon as possible, please reply as soon as you can.

Thank you!

Best regards,  
Pietari

Begin forwarded message:

**From:** "Ripatti, Samuli" <[samuli.ripatti@helsinki.fi](mailto:samuli.ripatti@helsinki.fi)>  
**Subject:** Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 15.1.2020 at 22.53.26 EET  
**To:** "Ripatti, Jaakko P" <[pietari.ripatti@helsinki.fi](mailto:pietari.ripatti@helsinki.fi)>



**From:** Priit Palta priit.palta@helsinki.fi  
**Subject:** Re: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 17.1.2020 at 7.52  
**To:** Pietari Ripatti pietari.ripatti@gmail.com

PP

I do agree with these additional authors being added.

Kind regards,  
Priit Palta

On Thu, 16 Jan 2020, 07:06 Pietari Ripatti, <pietari.ripatti@gmail.com> wrote:  
Dear co-authors,

As per journal's policy, I'd require your statement attesting to your agreement to add new authors to the manuscript. During the first major revision, we added four additional authors: Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén. Yu, Jake, and Taru were responsible for performing the revised lipid GWAS in the UKBB. Elisabeth is the co-lead-PI for GeneRISK, in which the optimal rho parameter for LDpred was tested. Their contributions were very substantial and I think they deserve author status.

Please email the statements directly to me and I'll forward them to the journal all at once. As we want to get the submission going as soon as possible, please reply as soon as you can.

Thank you!

Best regards,  
Pietari

Begin forwarded message:

**From:** "Ripatti, Samuli" <samuli.ripatti@helsinki.fi>  
**Subject:** Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 15.1.2020 at 22.53.26 EET  
**To:** "Ripatti, Jaakko P" <pietari.ripatti@helsinki.fi>

Sent from my iPhone

Begin forwarded message:

**From:** "martin.banigan@heart.org" <martin.banigan@heart.org>  
**Date:** 15. January 2020 at 15.08.06 GMT-5  
**To:** "Ripatti, Samuli" <samuli.ripatti@helsinki.fi>  
**Subject:** CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Reply-To:** martin.banigan@heart.org

Dear Prof. Ripatti,

In checking in your manuscript submitted to *Circulation: Genomic and Precision Medicine* it has come to our attention that the following must be addressed before we can release your manuscript to the Editor for consideration.

1. Per journal policy, if an author(s) is added to the manuscript, all other authors must provide a statement attesting to his/her agreement to the changes. Thus, all authors must approve the addition of the four authors added in the previous iteration of this manuscript. The statements can be emailed to [martin.banigan@heart.org](mailto:martin.banigan@heart.org). Alternatively, the statements can be uploaded as supplemental material.
2. If possible, please provide the final figures in TIF or EPS file format.
3. You must use the following symbols in the following order for the footnotes of your figures: \*, †, ‡, {section sign}, ll, #, \*\*, ††, ‡‡, etc.
4. Please remove the figure and table placeholders in the manuscript. Each item should only be cited parenthetically--the publisher will place the figures and tables where needed.
5. Please relabel the supplemental figures and tables--"Figure S1", etc. as opposed to "S1 Figure".

Your paper has been placed back in the Author Approval Folder where you may access via the following link:

<https://circgen-submit.aha-journals.org/cgi-bin/main.plex?el=A3Hp6CaZi6C4QGB4F6A9fdEyMaduU0qeXTPbO9vTASEwZ>

Please make the correction(s) as specified above and resubmit your paper following the same steps as before.

**From:** Freimer, Nelson B. NFreimer@mednet.ucla.edu  
**Subject:** Re: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 16.1.2020 at 7.15  
**To:** Pietari Ripatti pietari.ripatti@gmail.com

NF

I agree to adding the four additional authors as mentioned below  
Nelson

On Jan 15, 2020, at 9:06 PM, Pietari Ripatti <pietari.ripatti@gmail.com> wrote:

**CAUTION - EXTERNAL EMAIL: Do not click links or open attachments unless you recognize the sender.**

Dear co-authors,

As per journal's policy, I'd require your statement attesting to your agreement to add new authors to the manuscript. During the first major revision, we added four additional authors: Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén. Yu, Jake, and Taru were responsible for performing the revised lipid GWAS in the UKBB. Elisabeth is the co-lead-PI for GeneRISK, in which the optimal rho parameter for LDpred was tested. Their contributions were very substantial and I think they deserve author status.

Please email the statements directly to me and I'll forward them to the journal all at once. As we want to get the submission going as soon as possible, please reply as soon as you can.

Thank you!

Best regards,  
Pietari

Begin forwarded message:

**From:** "Ripatti, Samuli" <samuli.ripatti@helsinki.fi>  
**Subject:** Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 15.1.2020 at 22.53.26 EET  
**To:** "Ripatti, Jaakko P" <pietari.ripatti@helsinki.fi>

Sent from my iPhone

Begin forwarded message:

**From:** "martin.banigan@heart.org" <martin.banigan@heart.org>  
**Date:** 15. January 2020 at 15.08.06 GMT-5  
**To:** "Ripatti, Samuli" <samuli.ripatti@helsinki.fi>  
**Subject:** CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Reply-To:** martin.banigan@heart.org

Dear Prof. Ripatti,

In checking in your manuscript submitted to *Circulation: Genomic and Precision Medicine* it has come to our attention that the following must be addressed before we can release your manuscript to the Editor for consideration.

1. Per journal policy, if an author(s) is added to the manuscript, all other authors must provide a statement attesting to his/her agreement to the changes. Thus, all authors must approve the addition of the four authors added in the previous iteration of this manuscript. The statements can be emailed to [martin.banigan@heart.org](mailto:martin.banigan@heart.org). Alternatively, the statements can be uploaded as supplemental material.
2. If possible, please provide the final figures in TIF or EPS file format.
3. You must use the following symbols in the following order for the footnotes of your figures: \*, †, ‡, {section sign}, ll, #, \*\*, ††, ‡‡, etc.
4. Please remove the figure and table placeholders in the manuscript. Each item should only be cited parenthetically--the publisher will place the figures and tables where needed.
5. Please relabel the supplemental figures and tables--"Figure S1", etc. as opposed to "S1 Figure".

Your paper has been placed back in the Author Approval Folder where you may access via the following link:

<https://circgen-submit.aha-journals.org/cgi-bin/main.plex?el=A3Hp6CaZi6C4QGB4F6A9fdEyMaduU0qeXTPbO9vTASEwZ>

**From:** Salomaa Veikko (THL) [veikko.salomaa@thl.fi](mailto:veikko.salomaa@thl.fi)

**Subject:** RE: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission

**Date:** 16.1.2020 at 10.01

**To:** Pietari Ripatti [pietari.ripatti@gmail.com](mailto:pietari.ripatti@gmail.com), Joel Rämö [joel.ramo@helsinki.fi](mailto:joel.ramo@helsinki.fi), Nina Mars [nina.mars@helsinki.fi](mailto:nina.mars@helsinki.fi), Sanni Söderlund [sanni.soderlund@helsinki.fi](mailto:sanni.soderlund@helsinki.fi), Sanni Söderlund [sanni.soderlund@hus.fi](mailto:sanni.soderlund@hus.fi), Christian Benner [christian.benner@helsinki.fi](mailto:christian.benner@helsinki.fi), isurakka@umich.edu, Tuomo Kiiskinen [tuomo.kiiskinen@helsinki.fi](mailto:tuomo.kiiskinen@helsinki.fi), Havulinna, Aki S [aki.havulinna@helsinki.fi](mailto:aki.havulinna@helsinki.fi), Priit Palta [priit.palta@helsinki.fi](mailto:priit.palta@helsinki.fi), Freimer, Nelson B. [NFreimer@mednet.ucla.edu](mailto:NFreimer@mednet.ucla.edu), Matti Pirinen [matti.pirinen@helsinki.fi](mailto:matti.pirinen@helsinki.fi), Palotie, Aarno [aarno.palotie@helsinki.fi](mailto:aarno.palotie@helsinki.fi), Taskinen, Marja-Riitta [marja-riitta.taskinen@helsinki.fi](mailto:marja-riitta.taskinen@helsinki.fi), Samuli Ripatti [samuli.ripatti@helsinki.fi](mailto:samuli.ripatti@helsinki.fi)

SV

Dear Pietari,

I agree with adding the four coauthors as suggested.

Best,

Veikko

Veikko Salomaa, MD, PhD

Research Professor, emeritus

THL-National Institute for Health and Welfare

POB 30

Mannerheimintie 166

FI-00271 Helsinki, Finland

Phone: +358-29-524 8620

Mobile: +358-40-504 1649

[www.thl.fi](http://www.thl.fi)

---

**From:** Pietari Ripatti [<mailto:pietari.ripatti@gmail.com>]

**Sent:** 16. tammikuuta 2020 7:06

**To:** Joel Rämö; Nina Mars; Sanni Söderlund; Sanni Söderlund; Christian Benner; isurakka@umich.edu; Tuomo Kiiskinen; Havulinna, Aki S; Priit Palta; Freimer, Nelson B.; Salomaa Veikko (THL); Matti Pirinen; Palotie, Aarno; Taskinen, Marja-Riitta; Samuli Ripatti

**Subject:** ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission

Dear co-authors,

As per journal's policy, I'd require your statement attesting to your agreement to add new authors to the manuscript. During the first major revision, we added four additional authors: Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén. Yu, Jake, and Taru were responsible for performing the revised lipid GWAS in the UKBB. Elisabeth is the co-lead-PI for GeneRISK, in which the optimal rho parameter for LDpred was tested. Their contributions were very substantial and I think they deserve author status.

Please email the statements directly to me and I'll forward them to the journal all at once. As we want to get the submission going as soon as possible, please reply as soon as you can.

Thank you!

Best regards,  
Pietari

Begin forwarded message:

**From:** Priit Palta priit.palta@helsinki.fi  
**Subject:** Re: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 17.1.2020 at 7.52  
**To:** Pietari Ripatti pietari.ripatti@gmail.com

PP

I do agree with these additional authors being added.

Kind regards,  
Priit Palta

On Thu, 16 Jan 2020, 07:06 Pietari Ripatti, <[pietari.ripatti@gmail.com](mailto:pietari.ripatti@gmail.com)> wrote:  
Dear co-authors,

As per journal's policy, I'd require your statement attesting to your agreement to add new authors to the manuscript. During the first major revision, we added four additional authors: Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén. Yu, Jake, and Taru were responsible for performing the revised lipid GWAS in the UKBB. Elisabeth is the co-lead-PI for GeneRISK, in which the optimal rho parameter for LDpred was tested. Their contributions were very substantial and I think they deserve author status.

Please email the statements directly to me and I'll forward them to the journal all at once. As we want to get the submission going as soon as possible, please reply as soon as you can.

Thank you!

Best regards,  
Pietari

Begin forwarded message:

**From:** "Ripatti, Samuli" <[samuli.ripatti@helsinki.fi](mailto:samuli.ripatti@helsinki.fi)>  
**Subject:** Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 15.1.2020 at 22.53.26 EET  
**To:** "Ripatti, Jaakko P" <[pietari.ripatti@helsinki.fi](mailto:pietari.ripatti@helsinki.fi)>

Sent from my iPhone

Begin forwarded message:

**From:** "martin.banigan@heart.org" <[martin.banigan@heart.org](mailto:martin.banigan@heart.org)>  
**Date:** 15. January 2020 at 15.08.06 GMT-5  
**To:** "Ripatti, Samuli" <[samuli.ripatti@helsinki.fi](mailto:samuli.ripatti@helsinki.fi)>  
**Subject:** CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Reply-To:** [martin.banigan@heart.org](mailto:martin.banigan@heart.org)

Dear Prof. Ripatti,

In checking in your manuscript submitted to *Circulation: Genomic and Precision Medicine* it has come to our attention that the following must be addressed before we can release your manuscript to the Editor for consideration.

1. Per journal policy, if an author(s) is added to the manuscript, all other authors must provide a statement attesting to his/her agreement to the changes. Thus, all authors must approve the addition of the four authors added in the previous iteration of this manuscript. The statements can be emailed to [martin.banigan@heart.org](mailto:martin.banigan@heart.org). Alternatively, the statements can be uploaded as supplemental material.
2. If possible, please provide the final figures in TIF or EPS file format.
3. You must use the following symbols in the following order for the footnotes of your figures: \*, †, ‡, {section sign}, ll, #, \*\*, ††, ‡‡, etc.
4. Please remove the figure and table placeholders in the manuscript. Each item should only be cited parenthetically--the publisher will place the figures and tables where needed.
5. Please relabel the supplemental figures and tables--"Figure S1", etc. as opposed to "S1 Figure".

Your paper has been placed back in the Author Approval Folder where you may access via the following link:

<https://circgen-submit.aha-journals.org/cgi-bin/main.plex?el=A3Hp6CaZi6C4QGB4F6A9fdEyMaduU0qeXTPbO9vTASEwZ>

Please make the correction(s) as specified above and resubmit your paper following the same steps as before.

**From:** Matti Pirinen matti.pirinen@helsinki.fi  
**Subject:** Re: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 16.1.2020 at 10.25  
**To:** Pietari Ripatti pietari.ripatti@gmail.com

MP

I agree with adding to submission CIRCCVG/2019/002725 four additional authors: Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén.

Matti Pirinen  
University of Helsinki

On 16 Jan 2020, at 7.06, Pietari Ripatti <pietari.ripatti@gmail.com> wrote:

Dear co-authors,

As per journal's policy, I'd require your statement attesting to your agreement to add new authors to the manuscript. During the first major revision, we added four additional authors: Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén. Yu, Jake, and Taru were responsible for performing the revised lipid GWAS in the UKBB. Elisabeth is the co-lead-PI for GeneRISK, in which the optimal rho parameter for LDpred was tested. Their contributions were very substantial and I think they deserve author status.

Please email the statements directly to me and I'll forward them to the journal all at once. As we want to get the submission going as soon as possible, please reply as soon as you can.

Thank you!

Best regards,  
Pietari

Begin forwarded message:

**From:** "Ripatti, Samuli" <samuli.ripatti@helsinki.fi>  
**Subject:** Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 15.1.2020 at 22.53.26 EET  
**To:** "Ripatti, Jaakko P" <pietari.ripatti@helsinki.fi>

Sent from my iPhone

Begin forwarded message:

**From:** "martin.banigan@heart.org" <martin.banigan@heart.org>  
**Date:** 15. January 2020 at 15.08.06 GMT-5  
**To:** "Ripatti, Samuli" <samuli.ripatti@helsinki.fi>  
**Subject:** CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Reply-To:** martin.banigan@heart.org

Dear Prof. Ripatti,

In checking in your manuscript submitted to *Circulation: Genomic and Precision Medicine* it has come to our attention that the following must be addressed before we can release your manuscript to the Editor for consideration.

1. Per journal policy, if an author(s) is added to the manuscript, all other authors must provide a statement attesting to his/her agreement to the changes. Thus, all authors must approve the addition of the four authors added in the previous iteration of this manuscript. The statements can be emailed to [martin.banigan@heart.org](mailto:martin.banigan@heart.org). Alternatively, the statements can be uploaded as supplemental material.
2. If possible, please provide the final figures in TIF or EPS file format.
3. You must use the following symbols in the following order for the footnotes of your figures: \*, †, ‡, {section sign}, ll, #, \*\*, ††, ‡‡, etc.
4. Please remove the figure and table placeholders in the manuscript. Each item should only be cited parenthetically--the publisher will place the figures and tables where needed.
5. Please relabel the supplemental figures and tables--"Figure S1", etc. as opposed to "S1 Figure".

Your paper has been placed back in the Author Approval Folder where you may access via the following link:

<https://circgen-submit.aha-journals.org/cgi-bin/main.plex?el=A3Hp6CaZi6C4QGB4F6A9fdEyMaduU0qeXTPbO9vTASEwZ>

Please make the correction(s) as specified above and resubmit your paper following the same steps as before.

**From:** Palotie, Aarno aarno.palotie@helsinki.fi  
**Subject:** Re: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 16.1.2020 at 11.31  
**To:** Pietari Ripatti pietari.ripatti@gmail.com

AP

I agree with adding below mentioned authors to the manuscript

Aarno Palotie

---

**From:** Pietari Ripatti <pietari.ripatti@gmail.com>  
**Date:** Thursday, 16 January 2020 at 7.06  
**To:** "Rämö, Joel A T" <joel.ramo@helsinki.fi>, "Mars, Nina J" <nina.mars@helsinki.fi>, "Söderlund, Sanni M" <sanni.soderlund@helsinki.fi>, Sanni Söderlund <sanni.soderlund@hus.fi>, "Benner, Christian" <christian.benner@helsinki.fi>, "isurakka@umich.edu" <isurakka@umich.edu>, "Kiiskinen, Tuomo T J" <tuomo.kiiskinen@helsinki.fi>, "Havulinna, Aki S" <aki.havulinna@helsinki.fi>, "Palta, Priit" <priit.palta@helsinki.fi>, "Freimer, Nelson B." <NFreimer@mednet.ucla.edu>, Salomaa Veikko <veikko.salomaa@thl.fi>, "Pirinen, Matti J" <matti.pirinen@helsinki.fi>, "Palotie, Aarno" <aarno.palotie@helsinki.fi>, "Taskinen, Marja-Riitta" <marja-riitta.taskinen@helsinki.fi>, "Ripatti, Samuli" <samuli.ripatti@helsinki.fi>  
**Subject:** ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission

Dear co-authors,

As per journal's policy, I'd require your statement attesting to your agreement to add new authors to the manuscript. During the first major revision, we added four additional authors: Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén. Yu, Jake, and Taru were responsible for performing the revised lipid GWAS in the UKBB. Elisabeth is the co-lead-PI for GeneRISK, in which the optimal rho parameter for LDpred was tested. Their contributions were very substantial and I think they deserve author status.

Please email the statements directly to me and I'll forward them to the journal all at once. As we want to get the submission going as soon as possible, please reply as soon as you can.

Thank you!

Best regards,  
Pietari

Begin forwarded message:

**From:** "Ripatti, Samuli" <[samuli.ripatti@helsinki.fi](mailto:samuli.ripatti@helsinki.fi)>  
**Subject:** Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 15.1.2020 at 22.53.26 EET  
**To:** "Ripatti, Jaakko P" <[pietari.ripatti@helsinki.fi](mailto:pietari.ripatti@helsinki.fi)>

**From:** Priit Palta priit.palta@helsinki.fi  
**Subject:** Re: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 17.1.2020 at 7.52  
**To:** Pietari Ripatti pietari.ripatti@gmail.com

PP

I do agree with these additional authors being added.

Kind regards,  
Priit Palta

On Thu, 16 Jan 2020, 07:06 Pietari Ripatti, <pietari.ripatti@gmail.com> wrote:  
Dear co-authors,

As per journal's policy, I'd require your statement attesting to your agreement to add new authors to the manuscript. During the first major revision, we added four additional authors: Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén. Yu, Jake, and Taru were responsible for performing the revised lipid GWAS in the UKBB. Elisabeth is the co-lead-PI for GeneRISK, in which the optimal rho parameter for LDpred was tested. Their contributions were very substantial and I think they deserve author status.

Please email the statements directly to me and I'll forward them to the journal all at once. As we want to get the submission going as soon as possible, please reply as soon as you can.

Thank you!

Best regards,  
Pietari

Begin forwarded message:

**From:** "Ripatti, Samuli" <samuli.ripatti@helsinki.fi>  
**Subject:** Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 15.1.2020 at 22.53.26 EET  
**To:** "Ripatti, Jaakko P" <pietari.ripatti@helsinki.fi>

Sent from my iPhone

Begin forwarded message:

**From:** "martin.banigan@heart.org" <martin.banigan@heart.org>  
**Date:** 15. January 2020 at 15.08.06 GMT-5  
**To:** "Ripatti, Samuli" <samuli.ripatti@helsinki.fi>  
**Subject:** CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Reply-To:** martin.banigan@heart.org

Dear Prof. Ripatti,

In checking in your manuscript submitted to *Circulation: Genomic and Precision Medicine* it has come to our attention that the following must be addressed before we can release your manuscript to the Editor for consideration.

1. Per journal policy, if an author(s) is added to the manuscript, all other authors must provide a statement attesting to his/her agreement to the changes. Thus, all authors must approve the addition of the four authors added in the previous iteration of this manuscript. The statements can be emailed to [martin.banigan@heart.org](mailto:martin.banigan@heart.org). Alternatively, the statements can be uploaded as supplemental material.
2. If possible, please provide the final figures in TIF or EPS file format.
3. You must use the following symbols in the following order for the footnotes of your figures: \*, †, ‡, {section sign}, ll, #, \*\*, ††, ‡‡, etc.
4. Please remove the figure and table placeholders in the manuscript. Each item should only be cited parenthetically--the publisher will place the figures and tables where needed.
5. Please relabel the supplemental figures and tables--"Figure S1", etc. as opposed to "S1 Figure".

Your paper has been placed back in the Author Approval Folder where you may access via the following link:

<https://circgen-submit.aha-journals.org/cgi-bin/main.plex?el=A3Hp6CaZi6C4QGB4F6A9fdEyMaduU0qeXTPbO9vTASEwZ>

Please make the correction(s) as specified above and resubmit your paper following the same steps as before.

**From:** Taskinen, Marja-Riitta marja-riitta.taskinen@helsinki.fi

**Subject:** RE: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission

**Date:** 16.1.2020 at 10.43

**To:** Pietari Ripatti pietari.ripatti@gmail.com, Rämö, Joel A T joel.ramo@helsinki.fi, Mars, Nina J nina.mars@helsinki.fi, Söderlund, Sanni M sanni.soderlund@helsinki.fi, Sanni Söderlund sanni.soderlund@hus.fi, Benner, Christian christian.benner@helsinki.fi, isurakka@umich.edu, Kiiskinen, Tuomo T J tuomo.kiiskinen@helsinki.fi, Havulinna, Aki S aki.havulinna@helsinki.fi, Palta, Priit priit.palta@helsinki.fi, Freimer, Nelson B. NFreimer@mednet.ucla.edu, Salomaa Veikko veikko.salomaa@thl.fi, Pirinen, Matti J matti.pirinen@helsinki.fi, Palotie, Aarno aarno.palotie@helsinki.fi, Ripatti, Samuli samuli.ripatti@helsinki.fi

MT

Dear Joel and Samuli

I do agree with the author status of the added co-authors :Yu Fu, Jake LIN ,Taru Tukiainen and Elisabeth Widen .

with kind regards

Marja-Riitta

Marja-Riitta Taskinen  
Professor of Medicine  
University of Helsinki  
Research Programs Unit  
Biomedicum  
Haartmaninkatu 8, P.O.Box 700  
00029 Helsinki, Finland  
Tel: +358-9-4717 1990  
Fax: +358-9-4717 1992  
E-mail: [marja-riitta.taskinen@helsinki.fi](mailto:marja-riitta.taskinen@helsinki.fi)

---

**From:** Pietari Ripatti <pietari.ripatti@gmail.com>

**Sent:** torstai 16. tammikuuta 2020 7.06

**To:** Rämö, Joel A T <joel.ramo@helsinki.fi>; Mars, Nina J <nina.mars@helsinki.fi>; Söderlund, Sanni M <sanni.soderlund@helsinki.fi>; Sanni Söderlund <sanni.soderlund@hus.fi>; Benner, Christian <christian.benner@helsinki.fi>; isurakka@umich.edu; Kiiskinen, Tuomo T J <tuomo.kiiskinen@helsinki.fi>; Havulinna, Aki S <aki.havulinna@helsinki.fi>; Palta, Priit <priit.palta@helsinki.fi>; Freimer, Nelson B. <NFreimer@mednet.ucla.edu>; Salomaa Veikko <veikko.salomaa@thl.fi>; Pirinen, Matti J <matti.pirinen@helsinki.fi>; Palotie, Aarno <aarno.palotie@helsinki.fi>; Taskinen, Marja-Riitta <marja-riitta.taskinen@helsinki.fi>; Ripatti, Samuli <samuli.ripatti@helsinki.fi>

**Subject:** ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission

Dear co-authors,

As per journal's policy, I'd require your statement attesting to your agreement to add new authors to the manuscript. During the first major revision, we added four additional authors: Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén. Yu, Jake, and Taru were responsible for performing the revised lipid GWAS in the UKBB. Elisabeth is the co-lead-PI for GeneRISK, in which the optimal rho parameter for LDpred was tested. Their contributions were very substantial and I think they deserve author status.

Please email the statements directly to me and I'll forward them to the journal all at once. As we want to get the submission going as soon as possible, please reply as soon



**From:** Ripatti, Samuli samuli.ripatti@helsinki.fi  
**Subject:** Re: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 16.1.2020 at 16.04  
**To:** Pietari Ripatti pietari.ripatti@gmail.com



I am highly supportive in adding Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén as authors to the manuscript CIRCCVG/2019/002725R2

Samuli Ripatti

Samuli Ripatti, PhD, Professor  
Director, Center of Excellence in Complex Disease Genetics  
Vice Director, Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki  
Professor of Biometry, Faculty of Medicine, University of Helsinki, Finland  
Broad Institute of MIT and Harvard

[samuli.ripatti@helsinki.fi](mailto:samuli.ripatti@helsinki.fi)

CoECDG:  
<https://www.helsinki.fi/en/researchgroups/centre-of-excellence-in-complex-disease-genetics>

Twitter:  
@samrip  
@CoECDG

On Jan 16, 2020, at 7:06 AM, Pietari Ripatti <[pietari.ripatti@gmail.com](mailto:pietari.ripatti@gmail.com)> wrote:

Dear co-authors,

As per journal's policy, I'd require your statement attesting to your agreement to add new authors to the manuscript. During the first major revision, we added four additional authors: Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén. Yu, Jake, and Taru were responsible for performing the revised lipid GWAS in the UKBB. Elisabeth is the co-lead-PI for GeneRISK, in which the optimal rho parameter for LDpred was tested. Their contributions were very substantial and I think they deserve author status.

Please email the statements directly to me and I'll forward them to the journal all at once. As we want to get the submission going as soon as possible, please reply as soon as you can.

Thank you!

Best regards,  
Pietari

Begin forwarded message:

**From:** "Ripatti, Samuli" <[samuli.ripatti@helsinki.fi](mailto:samuli.ripatti@helsinki.fi)>  
**Subject:** Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 15.1.2020 at 22.53.26 EET  
**To:** "Ripatti, Jaakko P" <[pietari.ripatti@helsinki.fi](mailto:pietari.ripatti@helsinki.fi)>

Sent from my iPhone

Begin forwarded message:

**From:** "martin.banigan@heart.org" <[martin.banigan@heart.org](mailto:martin.banigan@heart.org)>  
**Date:** 15. January 2020 at 15.08.06 GMT-5  
**To:** "Ripatti, Samuli" <[samuli.ripatti@helsinki.fi](mailto:samuli.ripatti@helsinki.fi)>  
**Subject:** CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Reply-To:** [martin.banigan@heart.org](mailto:martin.banigan@heart.org)

Dear Prof. Ripatti,

In checking in your manuscript submitted to *Circulation: Genomic and Precision Medicine* it has come to our attention that the following must be addressed before we can release your manuscript to the Editor for consideration.

1. Per journal policy, if an author(s) is added to the manuscript, all other authors must provide a statement attesting to his/her agreement to the changes. Thus, all authors must approve the addition of the four authors added in the previous iteration of this manuscript. The statements can be emailed to [martin.banigan@heart.org](mailto:martin.banigan@heart.org). Alternatively, the statements can be uploaded as supplemental material.
2. If possible, please provide the final figures in TIF or EPS file format.
3. You must use the following symbols in the following order for the footnotes of your figures: \*, †, ‡, {section sign}, ll, #, \*\*,

**From:** Priit Palta priit.palta@helsinki.fi  
**Subject:** Re: ASAP, PLEASE RESPOND IMMEDIATELY Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 17.1.2020 at 7.52  
**To:** Pietari Ripatti pietari.ripatti@gmail.com

PP

I do agree with these additional authors being added.

Kind regards,  
Priit Palta

On Thu, 16 Jan 2020, 07:06 Pietari Ripatti, <pietari.ripatti@gmail.com> wrote:  
Dear co-authors,

As per journal's policy, I'd require your statement attesting to your agreement to add new authors to the manuscript. During the first major revision, we added four additional authors: Yu Fu, Jake Lin, Taru Tukiainen, and Elisabeth Widén. Yu, Jake, and Taru were responsible for performing the revised lipid GWAS in the UKBB. Elisabeth is the co-lead-PI for GeneRISK, in which the optimal rho parameter for LDpred was tested. Their contributions were very substantial and I think they deserve author status.

Please email the statements directly to me and I'll forward them to the journal all at once. As we want to get the submission going as soon as possible, please reply as soon as you can.

Thank you!

Best regards,  
Pietari

Begin forwarded message:

**From:** "Ripatti, Samuli" <samuli.ripatti@helsinki.fi>  
**Subject:** Fwd: CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Date:** 15.1.2020 at 22.53.26 EET  
**To:** "Ripatti, Jaakko P" <pietari.ripatti@helsinki.fi>

Sent from my iPhone

Begin forwarded message:

**From:** "martin.banigan@heart.org" <martin.banigan@heart.org>  
**Date:** 15. January 2020 at 15.08.06 GMT-5  
**To:** "Ripatti, Samuli" <samuli.ripatti@helsinki.fi>  
**Subject:** CIRCCVG/2019/002725R2 - Please Correct Your Submission  
**Reply-To:** martin.banigan@heart.org

Dear Prof. Ripatti,

In checking in your manuscript submitted to *Circulation: Genomic and Precision Medicine* it has come to our attention that the following must be addressed before we can release your manuscript to the Editor for consideration.

1. Per journal policy, if an author(s) is added to the manuscript, all other authors must provide a statement attesting to his/her agreement to the changes. Thus, all authors must approve the addition of the four authors added in the previous iteration of this manuscript. The statements can be emailed to [martin.banigan@heart.org](mailto:martin.banigan@heart.org). Alternatively, the statements can be uploaded as supplemental material.
2. If possible, please provide the final figures in TIF or EPS file format.
3. You must use the following symbols in the following order for the footnotes of your figures: \*, †, ‡, {section sign}, ll, #, \*\*, ††, ‡‡, etc.
4. Please remove the figure and table placeholders in the manuscript. Each item should only be cited parenthetically--the publisher will place the figures and tables where needed.
5. Please relabel the supplemental figures and tables--"Figure S1", etc. as opposed to "S1 Figure".

Your paper has been placed back in the Author Approval Folder where you may access via the following link:

<https://circgen-submit.aha-journals.org/cgi-bin/main.plex?el=A3Hp6CaZi6C4QGB4F6A9fdEyMaduU0qeXTPbO9vTASEwZ>

Please make the correction(s) as specified above and resubmit your paper following the same steps as before.